An approach towards enhancement of a screening library: The Next Generation Library Initiative (NGLI) at Bayer — against all odds?
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Pharmaceutical companies often refer to 'screening their library' when performing high-throughput screening (HTS) on a corporate compound collection to identify lead structures for small-molecule drug discovery programs. Characteristics of such a library, including the size, chemical space covered, and physicochemical properties, often determine the success of a screening campaign. Therefore, strategies to maintain and enhance the overall quality of screening collections are crucial to stay competitive and to cope with the 'novelty erosion' that is observed gradually. The Next Generation Library Initiative (NGLI), the enhancement of Bayer's HTS collection by 500000 newly designed compounds within 5 years, is addressing exactly this challenge. Here, we describe this collaborative project, which involves all internal medicinal chemists in a crowd-sourcing approach, as well as selected external partners, to reach this ambitious goal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PubChem Substance and Compound databases
Kim, S., Thiessen, P. A., Bolton, E. E., Chen, J., Fu, G., Gindulyte, A., Han, L., He, J., He, S., Shoemaker, B. A., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv951 · Cited by 5,436
Impact of high-throughput screening in biomedical research
Macarron, R., Banks, M. N., Bojanic, D., Burns, D. J., Cirovic, D. A., Garyantes, T., Green, D. V. S., Hertzberg, R. P., Janzen, W. P., Paslay, J. W., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3368 · Cited by 1,364
Reymond, J.-L. (2015) · Accounts of Chemical Research · doi:10.1021/ar500432k · Cited by 720
Cited by
Rethinking drug design in the artificial intelligence era
Schneider, P., Walters, W. P., Plowright, A. T., Sieroka, N., Listgarten, J., Goodnow, R. A., Fisher, J., Jansen, J. M., Duca, J. S., Rush, T. S., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0050-3 · Cited by 894
Photocatalysis in the Life Science Industry
Candish, L., Collins, K. D., Cook, G. C., Douglas, J. J., Gómez-Suárez, A., Jolit, A., & Keess, S. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00416 · Cited by 428
Generative molecular design in low data regimes
Moret, M., Friedrich, L., Grisoni, F., Merk, D., & Schneider, G. (2020) · Nature Machine Intelligence · doi:10.1038/s42256-020-0160-y · Cited by 219
Bayer’s in silico ADMET platform: a journey of machine learning over the past two decades
Göller, A. H., Kuhnke, L., Montanari, F., Bonin, A., Schneckener, S., ter Laak, A., Wichard, J., Lobell, M., & Hillisch, A. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.07.001 · Cited by 215
Self-citationO’ Donovan, D. H., De Fusco, C., Kuhnke, L., & Reichel, A. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01577 · Cited by 83
Metadata
- Authors
- Follmann, M., Briem, H., Steinmeyer, A., Hillisch, A., Schmitt, M. H., Haning, H., & Meier, H.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2019-03
- Volume
- 24
- Issue
- 3
- Pages
- 668-672
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W2903979853
- Cited by
- 53
- References
- 3
- FWCI
- 4.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An approach towards enhancement of a screening library: The Next Generation Library Initiative (NGLI) at Bayer — against all odds? https://app.cochat.ai/papers/10.1016/j.drudis.2018.12.003
- The paper
- Follmann, M., Briem, H., Steinmeyer, A., Hillisch, A., Schmitt, M. H., Haning, H., & Meier, H. (2019). An approach towards enhancement of a screening library: The Next Generation Library Initiative (NGLI) at Bayer — against all odds? Drug Discovery Today. https://doi.org/10.1016/j.drudis.2018.12.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.